Davos Hosts Psychedelic Medical Series
With increasing evidence suggesting that psychedelic-assisted therapy may be useful in the treatment of various mental health conditions, including post-traumatic stress disorder, substance-abuse disorders and depression, the emphasis on mental health treatment has grown these last few years. This has been fueled by the fallout of the coronavirus pandemic and the current war in Ukraine.
The annual meeting of the World Economic Forum is taking place this week in Davos-Klosters, Switzerland. At the event, top financial and political leaders in the world gather to discuss how to improve the state of the world. Coincidentally, the biggest names in the psychedelics field also gathered for the Medical Psychedelic Series, which was taking place at the same location. This comes as the mainstream acceptance of psychedelics grows and researchers learn more about the various benefits that these substances hold.
The medical series featured the meeting of world leaders with influencers, advocates, not-for-profit organizations, clinicians and drug-development experts. Energia Holdings Inc. CEO Marik Hazan stated that this meeting was a good opportunity for the psychedelics ecosystem to share their breakthroughs in psychedelic therapies with global leaders.
The medical series is being hosted by Hazan’s company and features panels and presentations designed to educate those in attendance about the potential of psychedelic therapies for mental health treatment. The main focus of the discussions is on the processes for regulatory approval of psychedelics and their therapeutic potential; patient access to these therapies; drug-development pipelines; biocultural preservation; and policy, safety and effectiveness.
The speakers being featured during the weeklong event include Beckley Foundation founder Amanda Fielding; Rachel Yehuda, a professor at the Icahn School of Medicine at Mount Sinai; Heffter Research Institute founder David Nichols; psychedelic medicine advocate Deepak Chopra; and well-known psychonaut Jason Silva.
Experiential sessions are also being conducted during the series, which are scheduled to run from May 21–26.
In total, more than 40 important opinion leaders from various parts of the globe have been taking part in the event. Additionally, a number of innovative psychedelic organizations are in attendance, including the Imperial College London, Compass Pathways, Maya Health and the Multidisciplinary Association for Psychedelic Studies.
Many hope that this forum will be the first of many and will help start conversations to address the unmet needs in mental health and offer a platform to establish meaningful partnerships and relationships to strengthen trust with the international community. The event may also help pave the way for the future of regulatory approval for psychedelic-assisted therapies, especially given the research being undertaken by entities that seek to commercialize novel mental health treatments. such as Silo Pharma Inc. (OTCQB: SILO).
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
With increasing evidence suggesting that psychedelic-assisted therapy may be useful in the treatment of various mental health conditions, including post-traumatic stress disorder, substance-abuse disorders and depression, the emphasis on mental health treatment has grown these last few years. This has been fueled by the fallout of the coronavirus pandemic and the current war in Ukraine.
The annual meeting of the World Economic Forum is taking place this week in Davos-Klosters, Switzerland. At the event, top financial and political leaders in the world gather to discuss how to improve the state of the world. Coincidentally, the biggest names in the psychedelics field also gathered for the Medical Psychedelic Series, which was taking place at the same location. This comes as the mainstream acceptance of psychedelics grows and researchers learn more about the various benefits that these substances hold.
The medical series featured the meeting of world leaders with influencers, advocates, not-for-profit organizations, clinicians and drug-development experts. Energia Holdings Inc. CEO Marik Hazan stated that this meeting was a good opportunity for the psychedelics ecosystem to share their breakthroughs in psychedelic therapies with global leaders.
The medical series is being hosted by Hazan’s company and features panels and presentations designed to educate those in attendance about the potential of psychedelic therapies for mental health treatment. The main focus of the discussions is on the processes for regulatory approval of psychedelics and their therapeutic potential; patient access to these therapies; drug-development pipelines; biocultural preservation; and policy, safety and effectiveness.
The speakers being featured during the weeklong event include Beckley Foundation founder Amanda Fielding; Rachel Yehuda, a professor at the Icahn School of Medicine at Mount Sinai; Heffter Research Institute founder David Nichols; psychedelic medicine advocate Deepak Chopra; and well-known psychonaut Jason Silva.
Experiential sessions are also being conducted during the series, which are scheduled to run from May 21–26.
In total, more than 40 important opinion leaders from various parts of the globe have been taking part in the event. Additionally, a number of innovative psychedelic organizations are in attendance, including the Imperial College London, Compass Pathways, Maya Health and the Multidisciplinary Association for Psychedelic Studies.
Many hope that this forum will be the first of many and will help start conversations to address the unmet needs in mental health and offer a platform to establish meaningful partnerships and relationships to strengthen trust with the international community. The event may also help pave the way for the future of regulatory approval for psychedelic-assisted therapies, especially given the research being undertaken by entities that seek to commercialize novel mental health treatments. such as Silo Pharma Inc. (OTCQB: SILO).
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
